BRPI0611717A2 - composto, composiÇço farmacÊutica e uso do composto - Google Patents

composto, composiÇço farmacÊutica e uso do composto

Info

Publication number
BRPI0611717A2
BRPI0611717A2 BRPI0611717-1A BRPI0611717A BRPI0611717A2 BR PI0611717 A2 BRPI0611717 A2 BR PI0611717A2 BR PI0611717 A BRPI0611717 A BR PI0611717A BR PI0611717 A2 BRPI0611717 A2 BR PI0611717A2
Authority
BR
Brazil
Prior art keywords
compound
compounds
pharmaceutical composition
akt
inhibit
Prior art date
Application number
BRPI0611717-1A
Other languages
English (en)
Inventor
Donna J Armstrong
Essa H Hu
Michael J Kelly
Mark E Layton
Yiwei Li
Jun Liang
Kevin J Rodzinak
Michael A Rossi
Philip E Sanderson
Jiabing Wang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0611717A2 publication Critical patent/BRPI0611717A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Abstract

COMPOSTO, COMPOSIÇçO FARMACÊUTICA E USO DO COMPOSTO. A presente invenção provê compostos nafliridina substituidos que inibem a atividade de Akt. Em particular, os compostos descritos seletivamente inibem uma ou duas das isoformas de Akt. A invenção também provê composições compreendendo estes compostos inibidores e métodos de inibir a atividade de Akt por administração dos compostos a um paciente em necessidade de tratamento de câncer.
BRPI0611717-1A 2005-06-10 2006-06-07 composto, composiÇço farmacÊutica e uso do composto BRPI0611717A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68972605P 2005-06-10 2005-06-10
US73418805P 2005-11-07 2005-11-07
PCT/US2006/022079 WO2006135627A2 (en) 2005-06-10 2006-06-07 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
BRPI0611717A2 true BRPI0611717A2 (pt) 2009-01-13

Family

ID=37532789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611717-1A BRPI0611717A2 (pt) 2005-06-10 2006-06-07 composto, composiÇço farmacÊutica e uso do composto

Country Status (22)

Country Link
US (1) US8008317B2 (pt)
EP (1) EP1898903B8 (pt)
JP (1) JP5055494B2 (pt)
KR (1) KR100959771B1 (pt)
AU (1) AU2006258124B8 (pt)
BR (1) BRPI0611717A2 (pt)
CA (1) CA2610888C (pt)
CR (1) CR9580A (pt)
DK (1) DK1898903T3 (pt)
EC (1) ECSP077980A (pt)
ES (1) ES2409168T3 (pt)
HR (1) HRP20130429T1 (pt)
IL (1) IL187690A (pt)
MX (1) MX2007015578A (pt)
NI (1) NI200700320A (pt)
NO (1) NO20080150L (pt)
NZ (1) NZ563423A (pt)
PL (1) PL1898903T3 (pt)
PT (1) PT1898903E (pt)
RU (1) RU2421454C2 (pt)
TW (1) TW200800166A (pt)
WO (1) WO2006135627A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
NZ563423A (en) 2005-06-10 2010-05-28 Merck Sharp & Dohme Inhibitors of AKT activity
TW200806670A (en) 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
EP2120951A4 (en) * 2006-12-06 2012-02-15 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
EP2139333A4 (en) * 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRIDO [3,2-E] [1,2,4] TRIAZOLO [4,3-C] PYRIMIDINE DERIVATIVES AS MODULATORS OF THE CANNABINOID-1 RECEPTOR
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
MX2010001746A (es) 2007-08-14 2010-03-10 Bayer Schering Pharma Ag Pirimidinas biciclicas fusionadas.
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8207169B2 (en) * 2008-06-03 2012-06-26 Msd K.K. Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D
US8536193B2 (en) * 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
BRPI0916218B1 (pt) 2008-07-17 2018-11-27 Bayer Cropscience Ag compostos heterocíclicos como composições praguicidas
JP2012516847A (ja) * 2009-02-02 2012-07-26 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US8957064B2 (en) 2009-02-13 2015-02-17 Bayer Intellectual Property Gmbh Fused pyrimidines
CN102361872B (zh) 2009-02-13 2014-12-03 拜耳知识产权有限责任公司 作为akt抑制剂的稠合嘧啶
EP2403339B1 (en) * 2009-03-06 2017-01-18 Merck Sharp & Dohme Corp. Combination cancer therapy with an akt inhibitor and other anticancer agents
US8614221B2 (en) * 2009-03-11 2013-12-24 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8168652B2 (en) 2009-03-12 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2266985A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
WO2011033265A1 (en) * 2009-09-18 2011-03-24 Almac Discovery Limited Pharmaceutical compounds
EP2513059A4 (en) * 2009-12-17 2013-06-05 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
ES2552841T3 (es) * 2010-07-12 2015-12-02 Bayer Intellectual Property Gmbh Imidazo[1,2-a]pirimidinas y -piridinas sustituidas
WO2012007500A2 (de) * 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
EA024890B1 (ru) 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CA2873661C (en) * 2012-05-17 2020-07-21 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
MX361136B (es) 2013-01-23 2018-11-28 Astrazeneca Ab Compuestos quimicos.
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
RU2016104643A (ru) 2013-08-12 2017-09-19 Токай Фармасьютикалз, Инк. Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения
EP3091016A1 (en) 2015-05-05 2016-11-09 Technische Universität Dortmund Kinase inhibitors and their use in cancer therapy
EP3388428B1 (en) * 2015-12-07 2021-08-04 Suzhou Sinovent Pharmaceuticals Company Five-membered heterocyclic amides wnt pathway inhibitor
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020533317A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド 特異的ａｋｔ３活性化剤およびその使用
WO2023081812A2 (en) * 2021-11-05 2023-05-11 Georgiamune Llc Akt3 modulators

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
WO2002083138A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP4394960B2 (ja) * 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
US20050130977A1 (en) 2002-04-08 2005-06-16 Lindsley Craig W. Inhibitors of akt activity
WO2003086404A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Fused quinoxaline derivatives as inhibitors of akt activity
AU2003226250B2 (en) 2002-04-08 2007-08-16 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2004018419A2 (en) * 2002-08-23 2004-03-04 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
EP1622616B1 (en) 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2004233827B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2004233835B2 (en) * 2003-04-24 2010-02-25 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DE602004026047D1 (de) 2003-04-24 2010-04-29 Merck Sharp & Dohme Hemmer der akt aktivität
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
JP4110324B2 (ja) 2003-10-15 2008-07-02 宇部興産株式会社 新規インダゾール誘導体
WO2005100356A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
US7544677B2 (en) * 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
JP2008521917A (ja) 2004-12-02 2008-06-26 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性のインヒビター
EP1827436A4 (en) 2004-12-15 2011-08-10 Merck Sharp & Dohme ACTIVITY INHIBITORS AKT
CA2597456A1 (en) * 2005-02-14 2006-08-31 Merck & Co., Inc. Inhibitors of akt activity
JP2008535915A (ja) 2005-04-12 2008-09-04 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
NZ563423A (en) 2005-06-10 2010-05-28 Merck Sharp & Dohme Inhibitors of AKT activity
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
US20100222321A1 (en) 2010-09-02
ECSP077980A (es) 2008-01-23
NZ563423A (en) 2010-05-28
WO2006135627A3 (en) 2008-07-31
TW200800166A (en) 2008-01-01
EP1898903B1 (en) 2013-03-27
HRP20130429T1 (en) 2013-06-30
CR9580A (es) 2008-09-23
EP1898903A2 (en) 2008-03-19
RU2008100045A (ru) 2009-07-20
AU2006258124B8 (en) 2010-01-07
PL1898903T3 (pl) 2013-08-30
EP1898903A4 (en) 2010-07-21
RU2421454C2 (ru) 2011-06-20
IL187690A0 (en) 2008-11-03
CA2610888A1 (en) 2006-12-21
WO2006135627A2 (en) 2006-12-21
NI200700320A (es) 2008-06-17
DK1898903T3 (da) 2013-07-01
KR20080016627A (ko) 2008-02-21
US8008317B2 (en) 2011-08-30
PT1898903E (pt) 2013-06-28
EP1898903B8 (en) 2013-05-15
NO20080150L (no) 2008-03-10
IL187690A (en) 2012-06-28
ES2409168T3 (es) 2013-06-25
JP5055494B2 (ja) 2012-10-24
AU2006258124B2 (en) 2009-09-03
JP2009501698A (ja) 2009-01-22
AU2006258124A1 (en) 2006-12-21
KR100959771B1 (ko) 2010-05-28
MX2007015578A (es) 2008-03-06
CA2610888C (en) 2011-02-08

Similar Documents

Publication Publication Date Title
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
BRPI0815708B8 (pt) composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
SV2011003786A (es) Compuestos quimicos 251
WO2006091395A3 (en) Inhibitors of akt activity
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BRPI0511139B8 (pt) compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
BRPI0519424B8 (pt) compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0622054B8 (pt) composto e composição farmacêutica
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
WO2006110638A3 (en) Inhibitors of akt activity
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112012006010A2 (pt) composto de glicina
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
WO2006068796A3 (en) Inhibitors of akt activity
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION, (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]